Assessment of Effect and Safety of Ripasudil (0.4%) in patients of Primary Open Angle Glaucoma / Ocular Hypertension
Article
| IMSEAR
| ID: sea-219968
Texte intégral:
1
Indice:
IMSEAR
Année:
2022
Type:
Article